{
  "trial_id": "NCT00061945",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Unequivocal histologic diagnosis of precursor B or precursor T lymphoblastic leukemia (World Health Organization [WHO] classification), L1 or L2 ALL or acute undifferentiated leukemia (AUL) (French-American-British Cooperative group [FAB] Classification); Burkitt-type ALL (FAB L3, surface immunoglobulin [SIg]+) are excluded",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "No prior treatment for leukemia with three permissible exceptions: Emergency leukapheresis II. Emergency treatment for hyperleukocytosis with hydroxyurea III. Cranial radiation therapy (RT) for central nervous system (CNS) leukostasis (one dose only)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "All patients must have a pre-treatment bone marrow or peripheral blood sample submitted for central immunophenotyping; only those patients who express CD52 >= 10% in the leukemia blast cell channel will be eligible to receive Campath-1H during module D, course IV",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "6",
    "trial_id": "NCT00061945",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}